Jun. 27 at 5:29 PM
$BCDA
there’s no real speculation or data on repeating the CardiAMP procedure. All their trials, including the ongoing Phase 3, treat it as a one-time, single-dose therapy. The two-year follow-up data showed durable benefits out to at least two years, and the company has highlighted that a single dose offers lasting effects.
The autologous nature of the cells does preserve the option for future retreatment if needed, but BioCardia hasn’t studied or promoted repeat dosing. Their focus is on one minimally invasive procedure using the patient’s own bone marrow cells. No clinical data exists yet on how often, or even if, it should be repeated for better outcomes.
